Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.

31 patients with thrombocytosis associated with myeloproliferative disorders were included in a prospective trial of long-term interferon therapy. 6 patients (19%) had side-effects which required withdrawal of interferon within one year. 22 patients (71%) achieved and maintained a complete response (platelet count less than 440 x 10(9)/l) for at least twelve months, with reduction or abolition of symptoms associated with thrombocytosis and a significant fall in bone-marrow megakaryocytes. At twelve months, 25 patients were randomly allocated to maintenance or withdrawal of interferon. Thrombocytosis recurred rapidly when treatment was stopped, but a second remission could be achieved by resumption of interferon therapy.
AuthorsH Gisslinger, H Ludwig, W Linkesch, A Chott, E Fritz, T Radaszkiewicz
JournalLancet (London, England) (Lancet) Vol. 1 Issue 8639 Pg. 634-7 (Mar 25 1989) ISSN: 0140-6736 [Print] ENGLAND
PMID2564458 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Interferon Type I
  • Aged
  • Aged, 80 and over
  • Bone Marrow Examination
  • Clinical Trials as Topic
  • Female
  • Humans
  • Interferon Type I (adverse effects, therapeutic use)
  • Male
  • Megakaryocytes
  • Middle Aged
  • Myeloproliferative Disorders (blood, complications)
  • Platelet Count (drug effects)
  • Random Allocation
  • Recurrence
  • Remission Induction
  • Thrombocytosis (blood, etiology, therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: